ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Texas' MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1988
Meetings & Education
Articles and Blogs
Fellows Abstract Competition
Patient Advocacy Organizations
State & Federal Resources
Find A Clinical Trial
Off-Label Use Literature
National Professional Organizations
TxSCO Corporate Members
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
FDA Approves Filgrastim Biosimilar for AML
On July 20, the Food and Drug Administration (FDA) approved filgrastim-aafi (Nivestym, Pfizer Inc.) for the treatment of chemotherapy-induced febrile neutropenia, acute myeloid leukemia (AML), patients with cancer receiving bone marrow transplant, peripheral blood progenitor cell collection and engraftment, and severe chronic neutropenia. This is the second approved biosimilar for filgrastim (Neupogen, Amgen) following the approval of filgrastim-sndz (Zarxio, Sandoz) in 2015.
Read the Pfizer corporate press release here.